Focus:
-
14 February 2019
AstraZeneca hopes FDA breakthrough therapy can rise above a string of recent failures
A respiratory syncytial virus is a common pneumovirus that causes seasonal lung and respiratory tract infections across the globe.
-
12 February 2019
Checkered data hinders Reata’s bardoxolone Phase II prospects
Creatinine is a waste product that is filtered through the kidneys and excreted in urine. Doctors measure blood creatinine levels to test kidney function.
-
12 February 2019
Even if approved Amgen’s biosimilar will have an uphill battle
Paroxysmal nocturnal haemoglobinuria, or PNH, is a rare, acquired, life-threatening blood disease.
-
12 February 2019
Roche’s Phase III Alban trial has five patients so far, source says
In the US, of the 70,000 new bladder cancer diagnoses, some 50,000 are non-muscle invasive bladder cancer patients.
-
8 February 2019
Immuno-oncology sees solid growth spurt
In an increasingly competitive landscape, immuno-oncology developers are taking multiple approaches to differentiate their products.
-
5 February 2019
Young adults with cancer need clinical pathways
Patients ages 15–39, having transitioned from the end of childhood into adulthood but without joining the heavily studied “older patient” demographic, tend to get stuck in a treatment impasse.
-
5 February 2019
Takeda’s dengue milestone is a time for cautious optimism
GlobalData believes these results should be treated with cautious optimism.
-
5 February 2019
Approval of Imbruvica bodes well for cancer treatment in 2019
AbbVie and Johnson & Johnson expect total sales of Imbruvica to reach $3.6 billion in 2019.
-
5 February 2019
Four anti-BCMA biologics expected to net $10 billion in revenue by 2027
GlobalData anticipates the total revenues from these four therapies to be approximately $10 billion, which will make up 35% of total MM drug revenues by 2027.
-
4 February 2019
World Cancer Day 2019: the oncology pricing debate continues
This year’s World Cancer Day occurs on 4 February, which also marks the launch of the three-year ‘I Am and I Will’ campaign urging for continued long-lasting impact, global awareness...